Zilovertamab vedotin regimen shows promise in diffuse large B-cell lymphoma

CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma.

Results of the trial, which evaluated the efficacy and safety of zilovertamab vedotin (Merck) plus rituximab (Rituxan; Genentech, Biogen) and gemcitabine-oxaliplatin, were presented at ASCO Annual Meeting.

Reference:

• Armand P, et al. Abstract 7005. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.

Published by:

Sources/Disclosures

Collapse

Source:

Caimi PF, et al. Strengthening the strike: Novel treatment approaches in relapsed-refractory large B-cell lymphoma. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.

Disclosures:
Caimi reports no relevant financial disclosures.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

“
data-action=”subscribe”>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio